Concepedia

Targeting and cytotoxicity of chimeric antigen receptor T cells grafted with PD1 extramembrane domain

Ang Zhang, Shenyu Wang, Yao Sun, Yikun Zhang, Long Zhao, Yang Yang, Yijian Zhang, Lei Xu, Yangyang Lei, Jie Du,

Experimental Hematology and Oncology · 2023 · 11 citations · 28 references

DOIFull text

Open access

Abstract

Our results revealed that CAR grafted with PD1 exhibits enhanced antitumor activity with lower cytokine release and no PD1-related off-target toxicity in tumor models that overexpress CD19 and PDL1. These findings suggest that our CAR design holds the potential for effectively addressing the PD1 signal.

References

28

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Dung T. Le, Jennifer N. Uram, Hao Wang et al. · New England Journal of Medicine · 2015 · 9.2K citations · Full text

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

Joseph A. Fraietta, Simon F. Lacey, Elena J. Orlando et al. · Nature Medicine · 2018 · 1.7K citations · Full text

, , +6

Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells

Omkar U. Kawalekar, Roddy S. O’Connor, Joseph A. Fraietta et al. · Immunity · 2016 · 1.1K citations · Full text

, , +14

Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

Leonid Cherkassky, Aurore Morello, Jonathan Villena‐Vargas et al. · Journal of Clinical Investigation · 2016 · 1K citations · Full text

CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells

Levi J. Rupp, Kathrin Schumann, Kole T. Roybal et al. · Scientific Reports · 2017 · 718 citations · Full text